ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...6162636465666768697071...129130»
  • ||||||||||  metformin / Generic mfg., ivermectin oral / Generic mfg., fluvoxamine / Generic mfg.
    Phase classification:  COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) -  Oct 7, 2021   
    P3,  N=1160, Recruiting, 
    Recovered patients mounted adequate antibody response. Phase classification: P2/3 --> P3
  • ||||||||||  prednisone / Generic mfg., ivermectin oral / Generic mfg.
    Journal:  Ophthalmomyiasis interna with invasion of the optic nerve. (Pubmed Central) -  Oct 6, 2021   
    Subretinal fly larvae can occasionally exit the eye by invading the optic nerve. Treatment of optic nerve involvement with ivermectin and prednisone can result in an excellent visual outcome.
  • ||||||||||  ivermectin oral / Generic mfg.
    [VIRTUAL] Trends in Top COVID-19 Questions Among a National Audience of Primary Care Clinicians () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1845;    
    PCCs nationally have gaps in knowledge around COVID-19 which can impact clinical decision-making. Based on our analysis of questions submitted by PCCs to infectious disease experts in a CME setting, the greatest gaps in knowledge were around vaccination, treatment, and testing with vaccination showing the greatest shift in interest over time.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly
    [VIRTUAL] Baricitinib in patients with severe pneumonia due to COVID-19 in Veracruz, Mexico () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1440;    
    Regarding the use of previous medications, we found that 29 (97%) patients had treatment with some medication, the most frequent: azithromycin (77%), ivermectin (53%) and dexamethasone (47%)... Baricitinib therapy in these patients with severe COVID-19 pneumonia who present with severe hypoxemia and cytokine storm presented good results by improving clinical status and pulmonary failure, with patients being cared for at home and avoiding mechanical ventilation.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19. () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1351;    
    Successful management of COVID-19 will require equitable access to treatment for all, not just those able to pay. Repurposed drugs can be manufactured at very low costs if shown to be clinically effective, and offers an affordable, widely available option for patients at all stages of the disease from pre-exposure prophylaxis to asymptotic and mild infections, through to critical care until vaccination coverage is expanded.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] CURE ID as a Tool for Curating and Analyzing Drugs Used in COVID-19 Clinical Trials () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1192;    
    CURE ID provides a broad view of the various drugs being researched and serves to keep the scientific community informed. Such a platform may help prevent duplication of efforts and help the scientific community with more coordinated research efforts and larger platform trials that can robustly answer scientific questions during a pandemic.